1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Global Hemophilia A Market 2015-2019

Global Hemophilia A Market 2015-2019

  • September 2015
  • -
  • Infiniti Research Limited
  • -
  • 68 pages

About hemophilia A
Hemophilia is a rare bleeding disorder caused by deficiency of clotting factors such as VIII and IX. It is an X-linked recessive disorder, which is more prevalent in males than in females. It is estimated that it affects around 400,000 people per year. The two major types of hemophilia are A and B. Hemophilia A, also called as classical hemophilia or factor VIII deficiency hemophilia, is caused by deficiency of clotting factor VIII. It is transmitted genetically from parent to child during birth. Recombinant clotting factors or plasma-derived clotting factors are being developed for the treatment of this disorder.

Technavio's analysts forecast the global hemophilia A drugs market to grow at a CAGR of 6.25% over the period 2014-2019.

Covered in this report
The report covers the current scenario and the growth prospects of the global hemophilia A drugs market for the period of 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various drugs used in the treatment and prevention of hemophilia A. In this report, the market is also segmented based on the type of therapy.

Technavio's report, Global Hemophilia A Drugs Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers APAC, Europe, and Americas; it also covers the landscape of the global hemophilia A drugs market and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

Key regions
- Americas
- APAC
- Europe

Key Vendors
- Baxter International
- Bayer's
- CSL Behring
- Novo Nordisk
- Pfizer

Other prominent vendors
- Alnylam Pharmaceuticals
- Amarna Therapeutics
- Asklepios
- Biogen Idec
- Catalyst Biosciences
- Dimension Therapeutics
- Dong-A Socio
- Emergent BioSolutions
- Grifols
- Inspiration Biopharmaceuticals
- Kedrion Biopharma
- Octapharma
- OPKO Health
- rEVO Biologics
- Sangamo BioSciences
- Spark Therapeutics
- UniQure

Market driver
- Development of drugs with prolonged action
- For a full, detailed list, view our report

Market challenge
- High cost of therapy
- For a full, detailed list, view our report

Market trend
- Advances in technology
- For a full, detailed list, view our report


Key Questions Answered in this Report
- What will the market size be in 2019 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

Table Of Contents

Global Hemophilia A Market 2015-2019
PART 01: Executive summary
Highlights
PART 02: Scope of the report
Market overview
Top-vendor offerings
PART 03: Market research methodology
Research methodology
Economic indicators
PART 04: Introduction
Key market highlights
PART 05: Disease overview
Understanding the disease
Risk factors
Signs and symptoms
Diagnosis
Treatment
Epidemiology
PART 06: Pipeline portfolio
Key information on pipeline candidates
PART 07: Market landscape
Market overview
Market size and forecast
Five forces analysis
PART 08: Segmentation by type of therapy
Plasma-derived therapies
Recombinant therapies
PART 09: Segmentation by disease management
On-demand therapy
Prophylaxis
Inhibitors
PART 10: Geographical segmentation
PART 11: Market drivers
PART 12: Impact of drivers
PART 13: Market challenges
PART 14: Impact of drivers and challenges
PART 15: Market trends
PART 16: Vendor landscape
Competitive scenario
Market share analysis 2014
Other prominent vendors
PART 17: Key vendor analysis
Baxter
Bayer HealthCare
CSL Behring
Pfizer
PART 18: Appendix
List of abbreviations
PART 19: Explore Technavio
?

List of Exhibits
Exhibit 01: Product offerings
Exhibit 02: Number of prevalence cases of hemophilia A in five countries 2011
Exhibit 03: Key late-stage drugs under development for hemophilia A
Exhibit 04: Global hemophilia A drugs market 2014-2019 ($ billions)
Exhibit 05: Five forces analysis
Exhibit 06: Global hemophilia A drugs market by type of therapy
Exhibit 07: Segmentation by type of therapy for hemophilia A
Exhibit 08: Global hemophilia A drugs market by disease management
Exhibit 09: Types of prophylaxis
Exhibit 10: Segmentation by disease management of hemophilia A
Exhibit 11: Segmentation of global hemophilia A drugs market by geography in 2014
Exhibit 12: Impact of drivers
Exhibit 13: Impact of drivers and challenges
Exhibit 14: Baxter: Global YoY growth and revenue of hemophilia products 2012-2014 ($ millions)
Exhibit 15: Baxter: Key takeaways
Exhibit 16: Novo Nordisk: Global YoY growth and revenue of hemophilia products 2012-2014 ($ millions)
Exhibit 17: Novo Nordisk: Key takeaways
Exhibit 18: Bayer: Global YoY growth and revenue of Kogenate FS 2012-2014 ($ millions)
Exhibit 19: Bayer's: Key takeaways
Exhibit 20: Pfizer: Global YoY growth and revenue of Xyntha/ReFactoAF 2012-2014 ($ millions)
Exhibit 21: Pfizer: Key takeaways
Exhibit 22: CSL Behring: Global YoY growth and revenue of hemophilia products 2013-2014 ($ millions)
Exhibit 23: CSL Behring: Key takeaways
Exhibit 24: CSL Behring: Product segmentation by revenue 2014
Exhibit 25: CSL Behring: Geographical segmentation by revenue 2014
Exhibit 26: Novo Nordisk: Business segmentation by revenue 2014
Exhibit 27: Novo Nordisk: Business segmentation by revenue 2013 and 2014
Exhibit 28: Novo Nordisk: Geographical segmentation by revenue 2014
Exhibit 29: Novo Nordisk: RandD expenditure 2014

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Hemophilia Treatment Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2016 - 2024

Hemophilia Treatment Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2016 - 2024

  • $ 5795
  • Industry report
  • January 2017
  • by Transparency Market Research

Global Hemophilia Treatment Drugs Market: Overview Hemophilia is a rare blood disorder. Hemophilia is a combination of two Greek words that is haima (blood) and philia (affection). Hemophilia is a hereditary ...

Epiomic Epidemiology Series: Polycythemia Vera Forecast in 27 Major Markets 2016-2026

Epiomic Epidemiology Series: Polycythemia Vera Forecast in 27 Major Markets 2016-2026

  • $ 5112
  • Industry report
  • December 2016
  • by Black Swan Analysis Ltd

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Polycythemia Vera in 27 Major Markets Polycythemia Vera (PV), also known as erythraemia, erythrocytosis, erythrocytosis megalosplenica, ...

Hemophilia A and B Therapeutics in Asia-Pacific Markets to 2022 - Growth Driven by Increasing Treatment-Receiving Pool, Launch of Long-Acting Replacement Therapies and Non-factor Therapy

Hemophilia A and B Therapeutics in Asia-Pacific Markets to 2022 - Growth Driven by Increasing Treatment-Receiving Pool, Launch of Long-Acting Replacement Therapies and Non-factor Therapy

  • $ 4995
  • Industry report
  • November 2016
  • by GBI Research

Hemophilia A and B Therapeutics in Asia-Pacific Markets to 2022 - Growth Driven by Increasing Treatment-Receiving Pool, Launch of Long-Acting Replacement Therapies and Non-factor Therapy Summary Hemophilia ...


ref:plp2015

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.